Answer
The safety and efficacy of Curosurf (poractant alfa) have not been evaluated in patients with renal or hepatic impairment.
Sources for this answer
- CurosurfChiesi Limited · emc · SmPC §4.2 Posology and method of administration · Version 7Document updated
Sources checked